Are NVST insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies NVST leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Stock Ratings / Health Care / NVST / insiders

PLSE (39) IRTC (47) ICUI (56) ATRC (63) ⌘ Pro Terminal →

Envista Holdings Corporation (NVST) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Where is NVST trading relative to its 50-day, 200-day, and 52-week technical levels?

NVST last traded at $24.71 (+5.10% on volume of 4,038,147 shares), positioning the stock +1.23% above its 50-day simple moving average ($24.41) and -3.96% below its 200-day simple moving average ($25.73). Across its 52-week range of $18.77 to $30.42, NVST sits at the 51.0% percentile with a 14-day RSI of 47.2 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($23.13 to $26.29).

$24.71 +5.10% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $24.89

Envista Holdings Corporation (NVST) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $3.78B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NVST Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NVST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Envista Holdings Corporation (NYSE: NVST) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $24.71 (+5.10% 1D, market cap $3.78B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, NVST ranks #323 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NVST compare to PLSE and IRTC in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), NVST carries a Roarable D (46/100 RQD), trailing P/E of 84.1x, gross margin of 54.7%, and ROIC of 5.1%. By comparison, PLSE (Pulse Biosciences Inc) holds a D- grade (39/100 RQD, P/E N/A, ROIC -30.7%, cap $3.73B) and IRTC (iRhythm Holdings Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -13.5%, cap $4.07B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NVST?

▼

Per NVST's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001757073), Envista Holdings Corporation generated $2.72B in revenue (+8.3% YoY), $47.0M in net income, and $230.4M in free cash flow against $5.68B in total assets and $1.45B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $24.89 (+0.73%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 8.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NVST)Realized 20D OHLCV Swing Band: ±6.4%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY NVST SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (26% of score)

Altman Z-Score 1.61 (DISTRESS RISK (<1.8)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+11/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 55% Net Buy • Cannibal Buyback (-0.96% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)

Capital intensity & 7.9% operating margin leave 13 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$22.82+1.6% Next Q

Q2 (-2Q)

Grade D$23.19+3.2% Next Q

Q3 (-1Q)

Grade D$23.94+3.2% Next Q

Current

Grade D$24.71-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NVST Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NVST currently carries a cautious 46/100 (D) rating due to Cash Engine Quality (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.41) and Max Pain ($25.95) forces dealer call-delta covering toward $31.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.96% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NVST• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NVST Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

NVST Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (NVST)

No recent open-market Form 4 cluster sales or emergency dumps flagged on NVST. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NVST)

✓Walkthrough of NVST's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NVST // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -4.26%📐 HORIZONTAL RANGE

2026-11-03O $24.61H $24.71L $23.51C $24.71VOL 3.73M

RES: $28.55SUP: $21.47SMA50: $24.41SMA200: $25.73

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NVST Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NVST Butterfly Map → + Track NVST →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

48.0%/yr Implied 5Y Growth

vs. +8.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NVST today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NVST. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NVST today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NVST)

Health Care Rank #323 of 1015 ⚔️ PLSE vs NVST Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NVST vs. PLSE, IRTC, ICUI, ATRC)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Envista Holdings Corporation (NVST) ranks #323 by composite RQD confidence (46/100, grade D) and #185 by equity capitalization ($3.78B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ATRC currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with NVST at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NVST ACTIVE Envista Holdings Corporation	D	46/100	84.1x	54.7%	5.1%	+5.10%	$3.78B	Benchmark Subject
PLSE Pulse Biosciences Inc	D-	39/100	—	-30.0%	-30.7%	+1.26%	$3.73B	/plse-vs-nvst →
IRTC iRhythm Holdings Inc.	D	47/100	—	70.6%	-13.5%	+2.27%	$4.07B	/irtc-vs-nvst →
ICUI ICU Medical Inc.	D+	56/100	—	36.8%	1.0%	-0.85%	$4.10B	/icui-vs-nvst →
ATRC AtriCure Inc.	C	63/100	—	75.0%	-1.9%	-2.24%	$3.12B	/atrc-vs-nvst →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001757073 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Envista Holdings Corporation (NVST) reported GAAP revenue of $2.72B (+8.3% vs. FY2024 revenue of $2.51B , and +6.0% cumulative change since FY2023) , GAAP net income of $47.0M, operating cash flow of $275.7M, and free cash flow of $230.4M (-23.9% YoY). On the balance sheet, NVST closed FY2025 with $5.68B in total assets against $1.45B in total debt (Altman Z-Score: 1.61, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.72B	$47.0M	$275.7M	$230.4M	$5.68B	$1.45B
FY2024 (FY)	2024-12-31	$2.51B	-$1.12B	$336.5M	$302.7M	$5.35B	$1.28B
FY2023 (FY)	2023-12-31	$2.57B	-$100.2M	$275.7M	$160.2M	$3.08B	$720.7M

3. NVST Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NVST stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does NVST compare to PLSE and IRTC in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for NVST?

Where is NVST trading relative to its 50-day, 200-day, and 52-week technical levels?

NVST last traded at $24.71 (+5.10% on volume of 4,038,147 shares), positioning the stock +1.23% above its 50-day simple moving average ($24.41) and -3.96% below its 200-day simple moving average ($25.73). Across its 52-week range of $18.77 to $30.42, NVST sits at the 51.0% percentile with a 14-day RSI of 47.2 (NEUTRAL RANGE) and an implied next-earnings move of ±6.4% ($23.13 to $26.29).

Direct Sub-Reports: NVST RQD Cockpit NVST 12M Forecast NVST Earnings & Move NVST Dividends & DRIP NVST Insiders & 13F NVST Whale Options NVST Profit Sankey NVST News & Why

ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

NVST — Envista Holdings Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Envista Holdings Corporation (NVST) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $24.71 (+5.10% 1D, market capitalization $3.78B).

Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of 5.1%, gross margin of 54.7%, operating margin of 7.9%, and free cash flow yield of 5.83%.
Whale 13F & Options Flow (8/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (8/20) + Forensic Balance Sheet (12/20): Incorporates a 0.93x equity beta, Altman Z-Score of 1.61, Piotroski F-Score of 9/9, and Debt/Equity of 0.47x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Envista Holdings Corporation is a NYSE-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry..0B. Per the market data, its gross margin is 54.7%, indicating a high-margin product mix.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Envista Holdings Corporation (NVST) reported $2.72B in annual revenue (up from $2.51B in FY2024, +8.3% YoY) and $47.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.57B revenue, -$100.2M net income) through FY2025, NVST scaled operating cash flow to $275.7M and free cash flow to $230.4M, backed by $5.68B in total assets against $1.45B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 5.83% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $18.77 – $30.42 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 84.1x trailing P/E and 16.5x EV/EBITDA against 7.9% operating margins and a 0.93x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector: Health Care; industry: Medical/Dental Instruments.

Key Question #1: Can NVST sustain or expand its 7.9% operating margin and 5.1% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.72B and free cash flow of $230.4M, how will capital allocation balance growth reinvestment against $1.45B in total debt?
Key Question #3: How sensitive is NVST's 78.2x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.93x)?

NVST Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Envista Holdings Corporation (NVST) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NVST Debate Forum (3) ↓

🟢 CATALYST Yahoo • 6d ago

Envista Q3 Earnings Ahead: Product Innovation to Drive Growth

NVST's Q3 earnings may have gained from Spark aligner growth, new product launches and improving margins. Can innovation drive another earnings beat?

Read Full Source ↗

🟢 CATALYST Yahoo • 6d ago

Envista (NVST) Earnings Expected to Grow: Should You Buy?

Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read Full Source ↗

🟡 MARKET WIRE Fintel • 6d ago

Envista Holdings Corporation Announces Publication of 2025 Sustainability Report

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 6d ago

Envista Announces Release of 2025 Sustainability Report

Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced the publication of its 2025 Sustainability Report. The report provides an update on Envista's progress in expanding access to dental care, supporting

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 7d ago

3 healthcare stocks we keep off our radar

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry h

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 19d ago

Every Tooth Deserves a Second Chance. Kerr Dental Introduces ZenFlex(TM) RT Rotary Retreatment File System

A dedicated retreatment file system designed for control while preserving tooth structure and improving procedural efficiency.POMONA, CA / ACCESS Newswire / October 15, 2026 / today announced the launch of ZenFlex™ RT Ro

Read Full Source ↗

🔴 RISK WATCH Benzinga • 19d ago

This Align Technology Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Analysts downgraded Envista, Cirrus Logic, ZTO Express, Align Technology and Par Pacific, with mixed price-target changes.

Read Full Source ↗

🔴 RISK WATCH Benzinga • 19d ago

Baird Downgrades Envista Holdings to Neutral, Lowers Price Target to $26

Baird analyst Jeff Johnson downgrades Envista Holdings (NYSE:NVST) from Outperform to Neutral and lowers the price target from $34 to $26.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NVST Bull vs. Bear Conversation Board — What's Your Call at $24.71?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NVST 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $28.92 (+23.0%)

📌 Pinned Debate

FY 2025 returned to positive operating income of $216.1M and free cash flow of $230.4M, with a Piotroski F-Score of 9/9.

The street is overcomplicating Envista Holdings Corporation (NVST). FY 2025 returned to positive operating income of $216.1M and free cash flow of $230.4M, with a Piotroski F-Score of 9/9.. With an RQD score of 46/100 (D) and Forensic Balance Sheet at 12/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $25.39.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 8/20 institutional whale-flow stock at $23.51 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $17.63 (-25.0%)

Spot @ $23.51

A P/E (TTM) of 84.1 on EPS of 0.29, with ROIC of 5.1% and an RQD distribution warning, leaves little earnings support for the price.

Sitting on the sidelines or leaning short NVST above $23.51. A P/E (TTM) of 84.1 on EPS of 0.29, with ROIC of 5.1% and an RQD distribution warning, leaves little earnings support for the price.. Until Fundamental Cash Engine (7/20) and FCF yield (5.83%) inflect higher, upside is capped near $30.42.